clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Infant, Premature, Diseases D007235 7 associated lipids
Parkinson Disease D010300 53 associated lipids
Monoclonal Gammopathy of Undetermined Significance D008998 2 associated lipids
Influenza, Human D007251 11 associated lipids
Lymphadenitis D008199 8 associated lipids
Drug Eruptions D003875 30 associated lipids
Skin Diseases, Infectious D012874 7 associated lipids
Eye Infections, Bacterial D015818 3 associated lipids
Synovitis D013585 15 associated lipids
Peptic Ulcer Perforation D010439 3 associated lipids
Carcinoma, Lewis Lung D018827 22 associated lipids
Renal Insufficiency D051437 8 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Genetic Predisposition to Disease D020022 24 associated lipids
Plaque, Atherosclerotic D058226 7 associated lipids
Insulin Resistance D007333 99 associated lipids
Liver Failure, Acute D017114 11 associated lipids
Periodontal Attachment Loss D017622 7 associated lipids
Bacteremia D016470 9 associated lipids
Hemophilia A D006467 10 associated lipids
Encephalitis D004660 15 associated lipids
Barrett Esophagus D001471 3 associated lipids
Rhabdomyolysis D012206 9 associated lipids
Gingival Overgrowth D019214 7 associated lipids
Meningitis, Bacterial D016920 6 associated lipids
Actinomycetales Infections D000193 4 associated lipids
Pneumonia, Bacterial D018410 16 associated lipids
Rosacea D012393 13 associated lipids
Psychoses, Substance-Induced D011605 7 associated lipids
Neurotoxicity Syndromes D020258 34 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Esophagitis, Peptic D004942 4 associated lipids
Helicobacter Infections D016481 21 associated lipids
Dermatitis, Phototoxic D017484 4 associated lipids
Keratoconjunctivitis D007637 3 associated lipids
Gastroesophageal Reflux D005764 10 associated lipids
Community-Acquired Infections D017714 8 associated lipids
Mycobacterium avium-intracellulare Infection D015270 4 associated lipids
Hand Dermatoses D006229 5 associated lipids
Gastritis, Atrophic D005757 4 associated lipids
Ergotism D004881 4 associated lipids
Ecchymosis D004438 3 associated lipids
AIDS-Related Opportunistic Infections D017088 9 associated lipids
Psychophysiologic Disorders D011602 3 associated lipids
Dyspepsia D004415 5 associated lipids
Skin Diseases, Bacterial D017192 8 associated lipids
Giardiasis D005873 3 associated lipids
Common Variable Immunodeficiency D017074 4 associated lipids
Purpura, Thrombocytopenic, Idiopathic D016553 4 associated lipids
Peptic Ulcer Hemorrhage D010438 4 associated lipids
Eye Injuries, Penetrating D015807 2 associated lipids
Prurigo D011536 4 associated lipids
Chlamydia Infections D002690 7 associated lipids
Legionnaires' Disease D007877 4 associated lipids
Whooping Cough D014917 6 associated lipids
Urethritis D014526 9 associated lipids
Boutonneuse Fever D001907 5 associated lipids
Fistula D005402 8 associated lipids
Dermatitis, Exfoliative D003873 10 associated lipids
Confusion D003221 4 associated lipids
Uveitis, Anterior D014606 11 associated lipids
Chromoblastomycosis D002862 2 associated lipids
Soft Tissue Injuries D017695 2 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Bronchiectasis D001987 7 associated lipids
Bronchiolitis Obliterans D001989 8 associated lipids
Parotitis D010309 4 associated lipids
Iris Diseases D007499 2 associated lipids
Exanthema D005076 11 associated lipids
Bronchiolitis D001988 6 associated lipids
Conjunctival Neoplasms D003230 3 associated lipids
Chlamydophila Infections D023521 4 associated lipids
Ureteral Diseases D014515 3 associated lipids
IgA Deficiency D017098 2 associated lipids
Cryptogenic Organizing Pneumonia D018549 3 associated lipids
Ureaplasma Infections D016869 5 associated lipids
Erythema Nodosum D004893 5 associated lipids
Soft Tissue Infections D018461 2 associated lipids
alpha 1-Antitrypsin Deficiency D019896 3 associated lipids
Pleuropneumonia D011001 3 associated lipids
Cytomegalovirus Retinitis D017726 2 associated lipids
Still's Disease, Adult-Onset D016706 2 associated lipids
Leprosy, Borderline D015439 3 associated lipids
Discitis D015299 2 associated lipids
Cardiovascular Abnormalities D018376 2 associated lipids
Pneumonia, Mycoplasma D011019 6 associated lipids
Desulfovibrionaceae Infections D045824 5 associated lipids
Periodontal Abscess D010508 2 associated lipids
Sexually Transmitted Diseases, Bacterial D015231 5 associated lipids
Conjunctivitis, Bacterial D003234 3 associated lipids
Psittacosis D009956 4 associated lipids
Angiomatosis, Bacillary D016917 2 associated lipids
Mycetoma D008271 4 associated lipids
Diphtheria D004165 2 associated lipids
Empyema D004653 3 associated lipids
Rickettsia Infections D012282 5 associated lipids
Sporotrichosis D013174 3 associated lipids
Pleural Diseases D010995 4 associated lipids
Bartonella Infections D001474 3 associated lipids
Lymphangitis D008205 4 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Zhang X and Hu C Selecting optimal columns for clarithromycin impurity analysis according to the quantitative relationship of hydrophobic subtraction model. 2017 J Pharm Biomed Anal pmid:28024686
Liu W et al. Rapid detection of mutations in erm(41) and rrl associated with clarithromycin resistance in Mycobacterium abscessus complex by denaturing gradient gel electrophoresis. 2017 J. Microbiol. Methods pmid:29079298
Koh WJ et al. Mycobacterial Characteristics and Treatment Outcomes in Mycobacterium abscessus Lung Disease. 2017 Clin. Infect. Dis. pmid:28011608
Chang CH et al. Non-Tuberculous Mycobacteria Infection Following Autologous Fat Grafting on the Face. 2017 Aesthet Surg J pmid:29045552
Çekin AH et al. Use of probiotics as an adjuvant to sequential H. pylori eradication therapy: impact on eradication rates, treatment resistance, treatment-related side effects, and patient compliance. 2017 Turk J Gastroenterol pmid:28007678
Ikeue T et al. Pleuritis Caused by Mycobacterium kyorinense without Pulmonary Involvement. 2017 Intern. Med. pmid:28924121
Yamamoto S et al. Mitochondrial proteins NIP-SNAP-1 and -2 are a target for the immunomodulatory activity of clarithromycin, which involves NF-κB-mediated cytokine production. 2017 Biochem. Biophys. Res. Commun. pmid:27998764
Panozzo C et al. Chemicals or mutations that target mitochondrial translation can rescue the respiratory deficiency of yeast bcs1 mutants. 2017 Biochim. Biophys. Acta pmid:28888990
Santos MA et al. Nothing to (S)cough at: Pulmonary Mycobacterium avium Complex Infection. 2017 Am. J. Med. pmid:27984010
Smibert OC et al. Short Communication: Mycobacterium avium Complex Infection and Immune Reconstitution Inflammatory Syndrome Remain a Challenge in the Era of Effective Antiretroviral Therapy. 2017 AIDS Res. Hum. Retroviruses pmid:28791872
Hiroi S et al. Impact of health insurance coverage for gastritis on the trends in eradication therapy in Japan: retrospective observational study and simulation study based on real-world data. 2017 BMJ Open pmid:28760790
Jenkins H et al. Effect of Multiple Oral Doses of the Potent CYP3A4 Inhibitor Clarithromycin on the Pharmacokinetics of a Single Oral Dose of Vonoprazan: A Phase I, Open-Label, Sequential Design Study. 2017 Clin Drug Investig pmid:27928738
Takemoto Y et al. Disseminated Mycobacterium scrofulaceum Infection in an Immunocompetent Host. 2017 Intern. Med. pmid:28717096
Alba C et al. Antibiotic resistance in Helicobacter pylori. 2017 Curr. Opin. Infect. Dis. pmid:28704226
Mishima E et al. Acute Kidney Injury from Excessive Potentiation of Calcium-channel Blocker via Synergistic CYP3A4 Inhibition by Clarithromycin Plus Voriconazole. 2017 Intern. Med. pmid:28674358
Sun W et al. Synergistic drug combination effectively blocks Ebola virus infection. 2017 Antiviral Res. pmid:27890675
Shimoyama T et al. Randomized Trial Comparing Esomeprazole and Rabeprazole in First-line Eradication Therapy for Helicobacter pylori Infection based on the Serum Levels of Pepsinogens. 2017 Intern. Med. pmid:28674348
Hung IFN et al. Efficacy of Clarithromycin-Naproxen-Oseltamivir Combination in the Treatment of Patients Hospitalized for Influenza A(H3N2) Infection: An Open-label Randomized, Controlled, Phase IIb/III Trial. 2017 Chest pmid:27884765
Ustundag GH et al. The Effects of Synbiotic " B94 plus Inulin" Addition on Standard Triple Therapy of Eradication in Children. 2017 Can J Gastroenterol Hepatol pmid:28656129
Peng X et al. Gastric Juice-Based Real-Time PCR for Tailored Treatment: A Practical Approach. 2017 Int J Med Sci pmid:28638276
Ozturk O et al. Therapeutic success with bismuth-containing sequential and quadruple regimens in Helicobacter pylori eradication. 2017 Arab J Gastroenterol pmid:28601610
Alirezaei A et al. Helicobacter pylori Eradication With Levofloxacin or Clarithromycin in Dialysis Versus Nonuremic Patients. 2017 Iran J Kidney Dis pmid:28575885
Stieler Stewart AL et al. Effects of clarithromycin, azithromycin and rifampicin on terbutaline-induced sweating in foals. 2017 Equine Vet. J. pmid:28238211
Emmanuel R et al. Antimicrobial efficacy of drug blended biosynthesized colloidal gold nanoparticles from Justicia glauca against oral pathogens: A nanoantibiotic approach. 2017 Microb. Pathog. pmid:29101061
Larsen EL et al. Clarithromycin, trimethoprim, and penicillin and oxidative nucleic acid modifications in humans: randomised, controlled trials. 2017 Br J Clin Pharmacol pmid:28185274
Ono S et al. Vonoprazan improves the efficacy of Helicobacter pylori eradication therapy with a regimen consisting of clarithromycin and metronidazole in patients allergic to penicillin. 2017 Helicobacter pmid:28098408
Bichler EK et al. Clarithromycin increases neuronal excitability in CA3 pyramidal neurons through a reduction in GABAergic signaling. 2017 J. Neurophysiol. pmid:27733592
Gouin-Thibault I et al. Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin. 2017 J. Thromb. Haemost. pmid:27893182
Tsugawa K et al. Clarithromycin attenuates the expression of monocyte chemoattractant protein-1 by activating toll-like receptor 4 in human mesangial cells. 2017 Clin. Exp. Nephrol. pmid:27614743
Varma MV et al. Transporter-Mediated Hepatic Uptake Plays an Important Role in the Pharmacokinetics and Drug-Drug Interactions of Montelukast. 2017 Clin. Pharmacol. Ther. pmid:27648490
Huet D et al. [Pulmonary infection with Mycobacterium malmoense. Difficulties in diagnosis and treatment]. 2017 Rev Mal Respir pmid:27639948
Jia L et al. Synthesis and antibacterial evaluation of novel 11-O-carbamoyl clarithromycin ketolides. 2017 Bioorg. Med. Chem. Lett. pmid:28711353
Park J et al. Progression and Treatment Outcomes of Lung Disease Caused by Mycobacterium abscessus and Mycobacterium massiliense. 2017 Clin. Infect. Dis. pmid:28011609
Ishiguro N et al. Therapeutic efficacy of azithromycin, clarithromycin, minocycline and tosufloxacin against macrolide-resistant and macrolide-sensitive Mycoplasma pneumoniae pneumonia in pediatric patients. 2017 PLoS ONE pmid:28288170
Attaran B et al. Effect of biofilm formation by clinical isolates of on the efflux-mediated resistance to commonly used antibiotics. 2017 World J. Gastroenterol. pmid:28275296
Zerbetto De Palma G et al. Occurrence of Mutations in the Antimicrobial Target Genes Related to Levofloxacin, Clarithromycin, and Amoxicillin Resistance in Helicobacter pylori Isolates from Buenos Aires City. 2017 Microb. Drug Resist. pmid:27391421
Okuda M et al. Nationwide survey of Helicobacter pylori treatment for children and adolescents in Japan. 2017 Pediatr Int pmid:27223686
Bewick J et al. The value of a feasibility study into long-term macrolide therapy in chronic rhinosinusitis. 2017 Clin Otolaryngol pmid:27223120
Legendre T et al. [Antibiomania: Think of the manic syndrome secondary to antibiotic therapy]. 2017 Encephale pmid:27178256
Choi HS et al. Peritoneal Dialysis-Related Peritonitis Caused by Microbacterium paraoxydans. 2017 Jpn. J. Infect. Dis. pmid:27169951
Chang CT et al. Antibiotic treatment of zebrafish mycobacteriosis: tolerance and efficacy of treatments with tigecycline and clarithromycin. 2017 J. Fish Dis. pmid:28422304
Furuya H et al. SAPHO syndrome-like presentation of disseminated nontuberculous mycobacterial infection in a case with neutralizing anti-IFNγ autoantibody. 2017 Rheumatology (Oxford) pmid:28371927
Ye JF et al. Evaluation of first-line bismuth-containing 7-day concomitant quintuple therapy for Helicobacter pylori eradication. 2017 J Dig Dis pmid:29119724
Chang KH et al. Comparison of antibiotic regimens in preterm premature rupture of membranes: neonatal morbidity and 2-year follow-up of neurologic outcome. 2017 J. Matern. Fetal. Neonatal. Med. pmid:27687157
Abadi ATB Resistance to clarithromycin and gastroenterologist's persistence roles in nomination for Helicobacter pylori as high priority pathogen by World Health Organization. 2017 World J. Gastroenterol. pmid:29085187
Pastukh N et al. GenoType® HelicoDR test in comparison with histology and culture for Helicobacter pylori detection and identification of resistance mutations to clarithromycin and fluoroquinolones. 2017 Helicobacter pmid:29058343
Tognetti L et al. Bullous impetigo during interstitial pneumonitis. 2017 G Ital Dermatol Venereol pmid:29050448
Chen MJ et al. Impact of amoxicillin resistance on the efficacy of amoxicillin-containing regimens for Helicobacter pylori eradication: analysis of five randomized trials. 2017 J. Antimicrob. Chemother. pmid:28961996
Chew CA et al. The diagnosis and management of H. pylori infection in Singapore. 2017 Singapore Med J pmid:28536725
Gunnarsdottir AI et al. Antibiotic susceptibility of Helicobacter pylori in Iceland. 2017 Infect Dis (Lond) pmid:28440099
Manniello MD et al. Clarithromycin and N-acetylcysteine co-spray-dried powders for pulmonary drug delivery: A focus on drug solubility. 2017 Int J Pharm pmid:28377314
Van der Paardt AL et al. Safety and tolerability of clarithromycin in the treatment of multidrug-resistant tuberculosis. 2017 Eur. Respir. J. pmid:28331034
Souto Filho JTD et al. Long-term complete remission of primary gastric plasmacytoma following endoscopic resection. 2017 Ann. Hematol. pmid:28315923
Antonakos N et al. Decreased cytokine production by mononuclear cells after severe gram-negative infections: early clinical signs and association with final outcome. 2017 Crit Care pmid:28274246
Koratala A et al. Exit Site Infection in Peritoneal Dialysis; Need for Follow-Up on Cultures Despite Clinical Improvement. 2017 Blood Purif. pmid:28268216
Lin CM et al. Is ionizing radiation a risk factor to diffuse panbronchiolitis? 2017 QJM pmid:28069906
Oikawa R et al. Enrichment of Helicobacter pylori mutant strains after eradication therapy analyzed by gastric wash-based quantitative pyrosequencing. 2017 Tumour Biol. pmid:28990461
Radzikowska E et al. Cryptogenic organizing pneumonia-Results of treatment with clarithromycin versus corticosteroids-Observational study. 2017 PLoS ONE pmid:28945804
Chew KL et al. Predominance of clarithromycin-susceptible Mycobacterium massiliense subspecies: Characterization of the Mycobacterium abscessus complex at a tertiary acute care hospital. 2017 J. Med. Microbiol. pmid:28874233
Miura S et al. [Effective BiRd Therapy after the Addition of Clarithromycin for Lenalidomide and Dexamethasone Resistant Multiple Myeloma Ineligible for Stem Cell Transplantation]. 2017 Gan To Kagaku Ryoho pmid:28860442
McCallum GB et al. Antibiotics for persistent cough or wheeze following acute bronchiolitis in children. 2017 Cochrane Database Syst Rev pmid:28828759
de Ávila BE et al. Micromotor-enabled active drug delivery for in vivo treatment of stomach infection. 2017 Nat Commun pmid:28814725
Zhang D et al. Berberine containing quadruple therapy for initial Helicobacter pylori eradication: An open-label randomized phase IV trial. 2017 Medicine (Baltimore) pmid:28796053
Fraser AG Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori. 2017 Aliment. Pharmacol. Ther. pmid:28776748
Jung YS et al. Editorial: replacing standard proton pump inhibitors with vonoprazan may breathe new life into triple therapy for Helicobacter pylori-authors' reply. 2017 Aliment. Pharmacol. Ther. pmid:28776746
Makihara K et al. Clarithromycin co-administration does not increase irinotecan (CPT-11) toxicity in colorectal cancer patients. 2017 Cancer Chemother. Pharmacol. pmid:28711984
Tanabe H et al. Efficacy of Vonoprazan-Based Triple Therapy for Helicobacter pylori Eradication: A Multicenter Study and a Review of the Literature. 2017 Dig. Dis. Sci. pmid:28664410
Fohner AE et al. PharmGKB summary: Macrolide antibiotic pathway, pharmacokinetics/pharmacodynamics. 2017 Pharmacogenet. Genomics pmid:28146011
Turvey SL et al. Mycobacterium branderi infection: Case report and literature review of an unusual and difficult-to-treat non-tuberculous mycobacterium. 2017 Int. J. Infect. Dis. pmid:28268125
Kadota JI et al. The clinical efficacy of a clarithromycin-based regimen for Mycobacterium avium complex disease: A nationwide post-marketing study. 2017 J. Infect. Chemother. pmid:28254517
Ufuk A et al. In Vitro and in Silico Tools To Assess Extent of Cellular Uptake and Lysosomal Sequestration of Respiratory Drugs in Human Alveolar Macrophages. 2017 Mol. Pharm. pmid:28252969
Iwayama K et al. Long-term treatment of clarithromycin at a low concentration improves hydrogen peroxide-induced oxidant/antioxidant imbalance in human small airway epithelial cells by increasing Nrf2 mRNA expression. 2017 BMC Pharmacol Toxicol pmid:28235416
Komiya K et al. Clarithromycin attenuates IL-13-induced periostin production in human lung fibroblasts. 2017 Respir. Res. pmid:28219384
Sakurai K et al. Comparative study: Vonoprazan and proton pump inhibitors in eradication therapy. 2017 World J. Gastroenterol. pmid:28216974
Awan S et al. Is clarithromycin a potential treatment for cachexia in people with lung cancer? A feasibility study. 2017 Lung Cancer pmid:28213005
Su J et al. Efficacy of 1st-line bismuth-containing quadruple therapies with levofloxacin or clarithromycin for the eradication of Helicobacter pylori infection: A 1-week, open-label, randomized trial. 2017 Medicine (Baltimore) pmid:28207505
Branquinho D et al. Levofloxacin or Clarithromycin-based quadruple regimens: what is the best alternative as first-line treatment for Helicobacter pylori eradication in a country with high resistance rates for both antibiotics? 2017 BMC Gastroenterol pmid:28202013
Inukai K et al. Effect of gel formation on the dissolution behavior of clarithromycin tablets. 2017 Int J Pharm pmid:28196716
Miftahussurur M et al. Clarithromycin-Based Triple Therapy is Still Useful as an Initial Treatment for Infection in the Dominican Republic. 2017 Am. J. Trop. Med. Hyg. pmid:28193745
Quinn KL et al. Macrolides, Digoxin Toxicity and the Risk of Sudden Death: A Population-Based Study. 2017 Drug Saf pmid:28421551
Noh HM et al. Eradication Rate by Duration of Third-line Rescue Therapy with Levofloxacin after Helicobacter pylori Treatment Failure in Clinical Practice. 2016 Korean J Gastroenterol pmid:27871162
Yazdanbakhsh AR et al. Reduction of non-Betalactam Antibiotics COD by Combined Coagulation and Advanced Oxidation Processes. 2016 Water Environ. Res. pmid:28661328
Sancak S et al. Intestinal blood flow by Doppler ultrasound: the impact of clarithromycin treatment for feeding intolerance in preterm neonates. 2016 J. Matern. Fetal. Neonatal. Med. pmid:26135789
Ohe M et al. A case of lupus nephritis treated with clarithromycin, tacrolimus, and glucocorticoids. 2016 Kaohsiung J. Med. Sci. pmid:27638410
Cosme A et al. Antimicrobial Susceptibility-Guided Therapy Versus Empirical Concomitant Therapy for Eradication of Helicobacter pylori in a Region with High Rate of Clarithromycin Resistance. 2016 Helicobacter pmid:25982426
Ozeki K et al. Association of Hay Fever with the Failure of Helicobacter pylori Primary Eradication. 2016 Intern. Med. pmid:27374672
Campillo A et al. [Cuadruple concomitant non-bismuth therapy vs. classical triple therapy as first line therapy for Helicobacter pylori infection]. 2016 Med Clin (Barc) pmid:27374029
Khashei R et al. High rate of A2142G point mutation associated with clarithromycin resistance among Iranian Helicobacter pylori clinical isolates. 2016 APMIS pmid:27357065
Oberhofer E [Quadruple therapy is more effective against H. pylori]. 2016 MMW Fortschr Med pmid:27155683
Mayor S Short term increase in neuropsychiatric events is seen with H pylori treatment containing clarithromycin. 2016 BMJ pmid:27143325
Swaminathan A et al. Treating children for drug-resistant tuberculosis in Tajikistan with Group 5 medications. 2016 Int. J. Tuberc. Lung Dis. pmid:26970156
Wong IC Author's reply to Blake. 2016 BMJ pmid:26957514
Todo K et al. Severe Helicobacter pylori gastritis-related thrombocytopenia and iron deficiency anemia in an adolescent female. 2016 Ann. Hematol. pmid:26957356
Sun H et al. [Antimicrobial susceptibility of community-acquired respiratory tract pathogens isolated from class B hospitals in China during 2013 and 2014]. 2016 Zhonghua Jie He He Hu Xi Za Zhi pmid:26792053
Miglietta F et al. A rare case of Saprochaete capitata fungemia in a critical ill patient without hematologic and oncological disorders. 2016 Rev Esp Quimioter pmid:26785226
Eszik I et al. High dynamic range detection of Chlamydia trachomatis growth by direct quantitative PCR of the infected cells. 2016 J. Microbiol. Methods pmid:26578244
Jain SK et al. Lectin-Conjugated Clarithromycin and Acetohydroxamic Acid-Loaded PLGA Nanoparticles: a Novel Approach for Effective Treatment of H. pylori. 2016 AAPS PharmSciTech pmid:26566630
Chen CH et al. Mycobacterium abscessus complex bacteremia due to prostatitis after prostate biopsy. 2016 Indian J Tuberc pmid:27998503
Gehlot V et al. Low prevalence of clarithromycin-resistant Helicobacter pylori isolates with A2143G point mutation in the 23S rRNA gene in North India. 2016 J Glob Antimicrob Resist pmid:27530837
Shimizu T and Suzaki H Past, present and future of macrolide therapy for chronic rhinosinusitis in Japan. 2016 Auris Nasus Larynx pmid:26441370